1. , . Speculations on the functional anatomy of basal ganglia disorders. Annu Rev Neurosci 1983;6:73–94.
2. , , . The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366–75.
3. , . Update on models of basal ganglia function and dysfunction. Parkinsonism Relat Disord 2009;15 Suppl 3:S237–40.
4. , . Past, present, and future of the pathophysiological model of the basal ganglia. Front Neuroanat 2011;5:39.
5. , . Extrastriatal dopaminergic circuits of the basal ganglia. Front Neuroanat 2010;4:139.
6. , , , et al. Dual character, asynaptic and synaptic, of the dopamine innervation in adult rat neostriatum: a quantitative autoradiographic and immunocytochemical analysis. J Comp Neurol 1996;375:167–86.
7. , . Pathological basal ganglia activity in movement disorders. Neuroscience 2011 PMID: 21723919.
8. , , , et al. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 2004;318:121–34.
9. , . Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114:2283–301.
10. , . Synchronisation in the beta frequency-band – the bad boy of parkinsonism or an innocent bystander?Exp Neurol 2009;217:1–3.
11. , . Basal ganglia local field potential activity: character and functional significance in the human. Clin Neurophysiol 2005;116:2510–19.
12. , , , et al. Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson’s disease. J Neurosci 2001;21:1033–8.
13. , . Imaging neurodegeneration in Parkinson’s disease. Biochem Biophys Acta 2009;1792:722–9.
14. , , , et al. Which clinical sign of Parkinson’s disease best reflects the nigrostriatal lesion?Ann Neurol 1997;41:58–64.
15. , , , et al. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson’s disease in various Hoehn & Yahr stages. J Neurol 2007;254:185–90.
16. , , . Extrastriatal monoamine neuron function in Parkinson’s disease: an 18F-dopa PET study. Neurobiol Dis 2008;29:381–90.
17. , , , et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson’s disease. A 3D [18F]Dopa-PET study. Brain 1999;122:1637–50.
18. , , , et al. Plasticity of the nigropallidal pathway in Parkinson’s disease. Ann Neurol 2003;53:206–13.
19. , , , et al. 11C-WAY 100635 PET study. Tremor in Parkinson’s disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 2003;60:601–5.
20. , , , et al. Fatigue in Parkinson’s disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010;133:3434–43.
21. , , , et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol 2006;253:42–7.
22. , , , et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009;73:1670–6.
23. , , , et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005;26:912–21.
24. , , , et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994;14:783–801.
25. , , , et al. Parkinson’s disease tremor-related metabolic network: characterization, progression, and treatment effects. Neuroimage 2011;54:1244–53.
26. , , , et al. Executive processes in Parkinson’s disease: FDG-PET and network analysis. Hum Brain Mapp 2004;22:236–45.
27. , , , et al. Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson’s disease. Ann Neurol 1996;39:450–9.
28. , , , et al. Combining functional imaging with brain stimulation in Parkinson’s disease. Int Rev Psychiatry 2011;23:467–75.
29. , , , et al. Impaired mesial frontal and putamen activation in Parkinson’s disease: a PET study. Ann Neurol 1992;32:151–61.
30. , , , et al. Self-initiated versus externally triggered movements. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson’s disease subjects. Brain 1995;118:913–33.
31. , , , et al. Motor imagery in normal subjects and Parkinson’s disease patients: an H215O PET study. Neuroreport 2001;12:821–8.
32. , , , et al. Impaired activation of the supplementary motor area in Parkinson’s disease is reversed when akinesia is treated with apomorphine. Ann Neurol 1992;32:749–57.
33. , , , et al. Medial temporal lobe activation in Parkinson’s disease during fronto-striatal tasks revealed by PET: evidence for cortical reorganization?Mov Disord 1998;13 Suppl 2: 238.
34. , . The effects of surgical treatment of Parkinson’s disease on brain function: PET findings. Neurology 2000;55 Suppl 6:S52–9.
35. , . A functional MRI study of automatic movements in patients with Parkinson’s disease. Brain 2005;128:2250–9.
36. , , , et al. Compensatory cortical mechanisms in Parkinson’s disease evidenced with fMRI during the performance of pre-learned sequential movements. Brain Res 2007;1147:265–71.
37. , , , et al. Blood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson’s disease. Mov Disord 2010;25:2035–43.
38. , , , et al. Reliability analysis of the resting state can sensitively and specifically identify the presence of Parkinson disease. Neuroimage 2011; PMID: 21924367.
39. . Functional imaging in Huntington’s disease. Exp Neurol 2009;216:272–7.
40. , , , et al. Cortical dopamine dysfunction in symptomatic and premanifest Huntington’s disease gene carriers. Neurobiol Dis 2010;37:356–61.
41. , , . [11C]-raclopride-PET studies of the Huntington’s disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol 1998;43:253–5.
42. , , , et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington’s disease: a PET study. Brain 2003;126:1127–35.
43. , , , et al. Huntington’s disease progression. PET and clinical observations. Brain 1999;122:2353–63.
44. , , , et al. Positron emission tomography measures of benzodiazepine receptors in Huntington’s disease. Ann Neurol 1993;34:76–81.
45. , , , et al. 11C-diprenorphine binding in Huntington’s disease: a comparison of region of interest analysis with statistical parametric mapping. J Cereb Blood Flow Metab 1997;17:943–9.
46. , , , et al. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med 2010;51:1413–17.
47. , , , et al. Cerebral cortex and the clinical expression of Huntington’s disease: complexity and heterogeneity. Brain 2008;131:1057–68.
48. , , , et al. Metabolic network abnormalities in early Huntington’s disease: an [(18)F]FDG PET study. J Nucl Med 2001;42:1591–5.
49. , , , et al. Thalamic metabolism and symptom onset in preclinical Huntington’s disease. Brain 2007;130:2858–67.
50. , , , et al. Cortical control of movement in Huntington’s disease. A PET activation study. Brain 1997;120:1569–78.
51. , , , et al. Central motor processing in Huntington’s disease. A PET study. Brain 1997;120:1553–67.
52. , . An update on functional neuroimaging of parkinsonism and dystonia. Curr Opin Neurol 2006;19:412–19.
53. , , , et al. The functional neuroanatomy of dystonia. Neurobiol Dis 2011;42:185–201.
54. , , , et al. Primary dystonia: is abnormal functional brain architecture linked to genotype?Ann Neurol 2002;52:853–6.
55. , , , et al. Cerebellothalamocortical connectivity regulates penetrance in dystonia. J Neurosci 2009;29:9740–7.
56. , , , et al. In vivo evidence for GABA(A) receptor changes in the sensorimotor system in primary dystonia. Mov Disord 2011;26:852–7.
57. , , , et al. Abnormal striatal and thalamic dopamine neurotransmission: genotype-related features of dystonia. Neurology. 2009;72:2097–103.
58. , , . Contributions of positron emission tomography to elucidating the pathogenesis of idiopathic parkinsonism and dopa responsive dystonia. J Neural Transm Suppl 1997;50:47–52.
59. , , , et al. Striatal dopaminergic system in dopa-responsive dystonia: a multi-tracer PET study shows increased D2 receptors. J Neural Transm, 2004;111:59–67.
60. , , , et al. The metabolic pathology of dopa-responsive dystonia. Ann Neurol 2005;57:596–600.